These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

155 related items for PubMed ID: 38994592

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Potassium binders for chronic hyperkalaemia in people with chronic kidney disease.
    Natale P, Palmer SC, Ruospo M, Saglimbene VM, Strippoli GF.
    Cochrane Database Syst Rev; 2020 Jun 26; 6(6):CD013165. PubMed ID: 32588430
    [Abstract] [Full Text] [Related]

  • 3. Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients.
    Sullivan E, Ruegger M, Dunne I, Sutaria N, Towers WF.
    Am J Health Syst Pharm; 2023 Sep 07; 80(18):1238-1246. PubMed ID: 37335862
    [Abstract] [Full Text] [Related]

  • 4. Single Dose of Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate in Hospitalized Patients With Hyperkalemia.
    Yoo N, Song YB, Dubinsky I, Altshuler J.
    Ann Pharmacother; 2023 Sep 07; 57(9):1044-1052. PubMed ID: 36637028
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.
    Zhang Y, Xu R, Wang F, Liu Y, Xu J, Zhao N, Cheng F, Long L, Jia J, Lin S.
    Cardiovasc Drugs Ther; 2021 Oct 07; 35(5):1057-1066. PubMed ID: 33459923
    [Abstract] [Full Text] [Related]

  • 9. Long-term safety and efficacy of sodium zirconium cyclosilicate for hyperkalaemia in patients with mild/moderate versus severe/end-stage chronic kidney disease: comparative results from an open-label, Phase 3 study.
    Roger SD, Lavin PT, Lerma EV, McCullough PA, Butler J, Spinowitz BS, von Haehling S, Kosiborod M, Zhao J, Fishbane S, Packham DK.
    Nephrol Dial Transplant; 2021 Jan 01; 36(1):137-150. PubMed ID: 32030422
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Sodium zirconium cyclosilicate for the management of chronic hyperkalemia in kidney disease, a novel agent.
    Rastogi A, Hanna RM, Mkrttchyan A, Khalid M, Yaqoob S, Shaffer K, Dhawan P, Nobakht N, Kamgar M, Goshtaseb R, Sarmosyan K, Gnarini M, Wassef O, Lerma E.
    Expert Rev Clin Pharmacol; 2021 Sep 01; 14(9):1055-1064. PubMed ID: 34227913
    [Abstract] [Full Text] [Related]

  • 12. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD.
    Lepage L, Dufour AC, Doiron J, Handfield K, Desforges K, Bell R, Vallée M, Savoie M, Perreault S, Laurin LP, Pichette V, Lafrance JP.
    Clin J Am Soc Nephrol; 2015 Dec 07; 10(12):2136-42. PubMed ID: 26576619
    [Abstract] [Full Text] [Related]

  • 13. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.
    Takkar C, Nassar T, Qunibi W.
    Expert Opin Pharmacother; 2021 Jan 07; 22(1):19-28. PubMed ID: 32892634
    [Abstract] [Full Text] [Related]

  • 14. Serum potassium response to single-dose sodium zirconium cyclosilicate for the treatment of asymptomatic hyperkalemia in hospitalized patients.
    Lewis H, Stamper B, Yungkurth AC.
    Pharmacotherapy; 2024 Jan 07; 44(1):13-21. PubMed ID: 37475499
    [Abstract] [Full Text] [Related]

  • 15. Potassium responses to sodium zirconium cyclosilicate in hyperkalemic hemodialysis patients: post-hoc analysis of DIALIZE.
    Fishbane S, Ford M, Fukagawa M, McCafferty K, Rastogi A, Spinowitz B, Staroselskiy K, Vishnevskiy K, Lisovskaja V, Al-Shurbaji A, Guzman N, Bhandari S.
    BMC Nephrol; 2022 Feb 08; 23(1):59. PubMed ID: 35135481
    [Abstract] [Full Text] [Related]

  • 16. [Short-term effect of sodium zirconium cyclosilicate on potassium lowering in chronic kidney disease patients with hyperkalemia].
    Bai C, Shang J, Kang D, Yu W, Zhang FL, Zhang WF, Wu F, Guo RX, Zhang YD, Zhao ZZ.
    Zhonghua Yi Xue Za Zhi; 2020 Oct 20; 100(38):2997-3000. PubMed ID: 33086450
    [Abstract] [Full Text] [Related]

  • 17. Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose-response, phase 2/3 study.
    Kashihara N, Nishio T, Osonoi T, Saka Y, Imasawa T, Ohtake T, Mizuno H, Shibagaki Y, Kim H, Yajima T, Sarai N.
    Clin Exp Nephrol; 2020 Dec 20; 24(12):1144-1153. PubMed ID: 32779057
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project.
    Gonzalez-Ortiz A, Clase CM, Bosi A, Fu EL, Pérez-Guillé BE, Faucon AL, Evans M, Zoccali C, Carrero JJ.
    J Nephrol; 2024 May 20; 37(4):961-972. PubMed ID: 38236474
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of the tolerability and efficacy of sodium polystyrene sulfonate for long-term management of hyperkalemia in patients with chronic kidney disease.
    Georgianos PI, Liampas I, Kyriakou A, Vaios V, Raptis V, Savvidis N, Sioulis A, Liakopoulos V, Balaskas EV, Zebekakis PE.
    Int Urol Nephrol; 2017 Dec 20; 49(12):2217-2221. PubMed ID: 29027620
    [Abstract] [Full Text] [Related]

  • 20. Emergency Potassium Normalization Treatment Including Sodium Zirconium Cyclosilicate: A Phase II, Randomized, Double-blind, Placebo-controlled Study (ENERGIZE).
    Peacock WF, Rafique Z, Vishnevskiy K, Michelson E, Vishneva E, Zvereva T, Nahra R, Li D, Miller J.
    Acad Emerg Med; 2020 Jun 20; 27(6):475-486. PubMed ID: 32149451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.